Adult non-Hodgkin lymphoma treatment (PDQ®) health professional version. National Cancer Institute website. https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq#link/_334. Updated January 26, 2017. Accessed March 15, 2017.
Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2010;37(1):20-27.
Alemtuzumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/alemtuzumab. Published November 30, 2007. Updated October 23, 2014. Accessed January 16, 2017.
Becker JC, Lorenz E, Ugurel S, et al. Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget. 2017;8(45):79731-79741.
Bevacizumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/bevacizumab. Published October 5, 2006. Updated November 19, 2014. Accessed January 16, 2017.
Bhatia S, Afanasiev O, Nghiem P. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr Oncol Rep. 2011;13(6):488-497.
Bladder cancer treatment (PDQ®) health professional version. National Cancer Institute website. https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq#sectio/_180. Updated January 20, 2017. Accessed March 15, 2017.
Blinatumomab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/blinatumomab. Published December 22, 2014. Updated March 3, 2015. Accessed January 16, 2017.
Breast cancer treatment (PDQ®) health professional version. National Cancer Institute website. https://www.cancer.gov/types/breast/hp/breast-treatment-pdq#link/_1452. Updated February 3, 2017. Accessed March 15, 2017.
Brentuximab vedotin. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/brentuximabvedotin. Published September 12, 2011. Updated August 21, 2015. Accessed January 16, 2017.
Cancer immunotherapy: stomach cancer. Cancer Research Institute website. http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/stomach-cancer. Updated March 2016. Accessed January 23, 2017.
Cancer immunotherapy: multiple myeloma. Cancer Research Institute website. http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/multiple-myeloma. Updated September 2016. Accessed January 23, 2017.
Cancer immunotherapy: breast cancer. Cancer Research Institute website. http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/breast-cancer. Updated March 2016. Accessed January 23, 2017.
Cancer immunotherapy: colorectal cancer. Cancer Research Institute website. http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/colorectal-cancer. Updated March 2016. Accessed January 23, 2017.
Cancer immunotherapy: kidney cancer. Cancer Research Institute website. http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/kidney-cancer. Updated March 2016. Accessed January 23, 2017.
Cancer immunotherapy: cervical cancer. Cancer Research Institute website. http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/cervical-cancer. Updated February 2016. Accessed January 23, 2017.
Cancer immunotherapy: lymphoma. Cancer Research Institute website. http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/lymphoma. Updated July 2016. Accessed January 23, 2017.
Cervical cancer treatment (PDQ®) health professional version. National Cancer Institute website. https://www.cancer.gov/types/cervical/hp/cervical-treatment-pdq#link/_147. Updated January 31, 2017. Accessed March 15, 2017.
16. Cetuximab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/cetuximab. Published October 5, 2006. Updated October 23, 2014. Accessed January 16, 2017.
Clinical trials search results: recurrent melanoma. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/results?protocolsearchid=15768220&vers=2. Accessed March 15, 2017.
Colon cancer treatment (PDQ®) health professional version. National Cancer Institute website. https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq#link/_145. Updated February 3, 2017. Accessed March 15, 2017.
D'Angelo SP, Russell J, Hassel JC, et al. First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): preliminary data from an ongoing study. J Clin Oncol. 2017;35(15 suppl):9530.
Daratumumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/daratumumab. Published November 25, 2015. Updated December 12, 2016. Accessed January 16, 2017.
Elotuzumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/elotuzumab. Published December 8, 2015. Updated February 5, 2016. Accessed January 16, 2017.
FDA approves new immunotherapy drug for bladder cancer. National Cancer Institute website. https://www.cancer.gov/news-events/cancer-currents-blog/2016/fda-atezolizumab-bladder. Published June 7, 2016. Accessed January 16, 2017.
Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096-1100.
Gastric cancer treatment (PDQ®) health professional version. National Cancer Institute website. https://www.cancer.gov/types/stomach/hp/stomach-treatment-pdq#link/_81. Updated February 2, 2017. Accessed March 15, 2017.
Goh G, Walradt T, Markarov V, et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget. 2016;7(3):3403-3415.
Hoffman J. Pipeline series: melanoma. Cancer Therapy Advisor website. http://www.cancertherapyadvisor.com/skin-cancer/melanoma-pipeline-future-drug-treatment/article/487565/. Published April 4, 2016. Accessed January 23, 2017.
Hoffmann-La Roche. A study of atezolizumab plus cobimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated BRAFv600 mutation-positive participants with metastatic or unresectable locally advanced melanoma (NCT0290867). ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/NCT02908672. Updated October 2016. Accessed January 25, 2017.
Human papillomavirus (HPV) vaccines. National Cancer Institute website. https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet. Updated November 2, 2016. Accessed January 16, 2017.
Ibritumomab tiuxetan. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/ibritumomabtiuxetan. Published February 26, 2008. Updated July 31, 2014. Accessed January 16, 2017.
Ipilimumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/ipilimumab. Published April 21, 2011. Updated December 15, 2015. Accessed January 16, 2017.
Iyer JG, Blom A, Doumani R, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294-2301.
Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374-1385.
Lemos BD, Storer BE, Iyer JG, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63(5):751-761.
Melanoma treatment (PDQ®) health professional version. National Cancer Institute website. https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq#link/_681. Updated January 26, 2017. Accessed March 15, 2017.
Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54-63.
NCI dictionary of cancer terms: HER2/neu. National Cancer Institute website. https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=44945. Accessed January 17, 2017.
Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542-2552.
Nivolumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab. Published January 7, 2015. Updated November 11, 2016. Accessed January 16, 2017.
Non-small cell lung cancer treatment (PDQ®) health professional version. National Cancer Institute website. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq#link/_48622. Updated February 3, 2017. Accessed March 15, 2017.
Obinutuzumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/obinutuzumab. Published November 12, 2013. Updated March 4, 2016. Accessed January 16, 2017.
Ofatumumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/ofatumumab. Published November 30, 2009. Updated January 21, 2016. Accessed January 16, 2017.
Panitumumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/panitumumab. Published October 5, 2006. Updated October 23, 2014. Accessed January 16, 2017.
Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: current United States incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457-463.e2.
Peginterferon alfa-2b. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/peginterferon-alfa-2b. Published May 9, 2013. Updated July 26, 2016. Accessed January 16, 2017.
Pembrolizumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab. Published September 18, 2014. Updated December 20, 2016. Accessed January 16, 2017.
Pertuzumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/pertuzumab. Published July 13, 2012. Updated August 27, 2015. Accessed January 17, 2017.
Plasma cell neoplasms (including multiple myeloma) treatment (PDQ®) health professional version. National Cancer Institute website. https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq#link/_352_toc. Updated February 3, 2017. Accessed March 15, 2017.
Prostate cancer treatment (PDQ®) health professional version. National Cancer Institute website. https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq#link/_72. Updated January 26, 2017. Accessed March 15, 2017.
Ramucirumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/ramucirumab. Published May 8, 2014. Updated December 6, 2016. Accessed January 16, 2017.
Renal cell cancer treatment (PDQ®) health professional version. National Cancer Institute website. https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq#link/_67. Updated January 20, 2017. Accessed March 15, 2017.
Rituximab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/rituximab. Published October 5, 2006. Updated October 23, 2014. Accessed January 16, 2017.
Schadendorf D, Nghiem P, Bhatia S, et al. Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. Oncoimmunology. 2017;6(10):e1338237.
Sipuleucel-T. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/sipuleucel-T. Published June 28, 2010. Updated July 31, 2014. Accessed January 16, 2017.
Talimogene laherparepvec. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/talimogenelaherparepvec. Published November 3, 2015. Updated March 3, 2016. Accessed January 16, 2017.
Topalian SL, Bhatia S, Hollebecque A, et al. Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). Paper presented at: American Association for Cancer Research Annual Meeting; April 1-5, 2017; Washington, D. C. Abstract CT074.
Trastuzumab. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/drugs/trastuzumab. Published October 5, 2006. Updated November 8, 2016. Accessed January 16, 2017.
Wong SQ, Waldeck K, Vergara IA, et al. UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. Cancer Res. 2015;75(24):5228-5234.
Thank you for participating in this module. Click below to download the certificate.